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INTRODUCTION
In 1959, President Eisenhower declared that the government
should not get involved with birth control,1 but these words were not
heeded. On January 21, 2017, millions of people worldwide took part
in the Women’s March to protest against the government for human
rights, inclusive of women’s rights and healthcare reform.2 With the
possible repeal of the Affordable Care Act imminently closing in,3
women are left wondering if a male-dominated government truly
understands women’s contraceptive needs. Tom Price, the former
Secretary of the Department of Health and Human Services, previ-
ously showed a lack of financial understanding of birth control cover-
age when he made statements suggesting that there were not any
women incapable of affording birth control.4 This is obviously not
the case, when the unintended pregnancy rate is at almost fifty per-
cent, and there are masses of women living in poverty.5 After Senate
Republicans voted against a measure that proposed to pay for birth
control and mammograms, required insurance coverage for maternity
leave, and prevented insurance companies from charging enlarged
rates for preexisting conditions,6 it became evident that many politi-
cians just do not get it. Should something as important as birth control
be affected every time there is an election or a change of power? It
seems that Eisenhower may have had the right idea. The adoption of
a permanent resolution that provides stable and accessible birth con-
trol options may lessen the volatility of our system. Over-the-Counter
(OTC) access to oral contraception (OC) may be the solution and, given
that President Trump supports this idea,7 could be a viable option.
1. Elaine Tyler May, How the Catholic Church almost came to accept birth control—in
the 1960s, WASH. POST (Feb. 24, 2012), https://www.washingtonpost.com/opinions/how
-the-catholic-church-almost-came-to-accept-birth-control/2012/02/21/glQAdy1JYR_story
.html?utm_term=.8c0a74d670d0 [https://perma.cc/TB6C-AHAN].
2. See The March, WOMEN’S MARCH, https://www.womensmarch.com/march [https://
perma.cc/6NHG-ZX6E].
3. Maggie Haberman & Robert Pear, Trump Tells Congress to Repeal and Replace
Health Care Law ‘Very Quickly,’ N.Y. TIMES (Jan. 10, 2017), https://www.nytimes.com
/2017/01/10/us/repeal-affordable-care-act-donald-trump.html?_r=0 [https://perma.cc
/9FKX-NE7Y].
4. Olga Khazan, Tom Price: ‘Not One’ Woman Struggled to Afford Birth Control,
THE ATLANTIC (Nov. 29, 2016), http://www.theatlantic.com/health/archive/2016/11/tom
-price-not-one-woman-cant-afford-birth-control/509003 [https://perma.cc/4AKZ-6Z2Z].
5. Fact Sheet: Unintended Pregnancy in the United States, GUTTMACHER INST. (Sept.
2016), https://www.guttmacher.org/fact-sheet/unintended-pregnancy-united-states#6
[https://perma.cc/YB6X-JWL9] [hereinafter Unintended Pregnancy].
6. Becca Andrews, Republicans Are Coming for Your Free Birth Control, MOTHER
JONES (Jan. 12, 2017, 8:52 PM), http://www.motherjones.com/politics/2017/01/make
-birth-control-expensive-again [https://perma.cc/4WJ2-E4A6].
7. Susan Scutti, Trump supports birth control without a prescription, CNN (Sept. 16,
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“The most effective way to reduce abortion rates [and] to pre-
vent unintended pregnancy [is] by improving access to consistent,
effective, and affordable contraception.” 8 Currently, oral contracep-
tives are being held captive by physicians, drug makers, politicians,
and the Food and Drug Administration (FDA) because there are
incentives that are given more weight than the rights and comfort
of women.9 Often, unrelated, invasive procedures act as barriers to
acquiring the only thing that can prevent unwanted and unplanned
pregnancies.10 While men can walk into publicly funded clinics and
acquire contraception or sexual performance-enhancing drugs without
undergoing prostate exams, women are mandated to undergo unre-
lated pelvic examinations and medical services for contraception.11
In both of these cases, the opportunity to impose preventative health-
care arises, but only women are subject to these regulations of in-
equality.12 Women are left with a conundrum: do they submit to
these unethical practices to get their prescription, or do they roll the
dice and end up paying dire, lifelong consequences?
The average woman will spend roughly three years attempting
to get pregnant, pregnant and postpartum, and “three decades—more
than three-quarters of her reproductive life—trying to avoid an
unintended pregnancy.”13 Unplanned pregnancies have a public health
impact that leads to adverse medical outcomes for mothers and
children, including premature births, delayed prenatal care, and
mental and physical effects in children.14 Unfortunately, over the
last twenty years, the rate of unintended pregnancies has consis-
tently “account[ed] for approximately 50% of all pregnancies.”15
These rates are significantly greater than those of other developed
2016, 4:10 PM), http://www.cnn.com/2016/09/15/health/trump-contraceptives-without
-prescription [https://perma.cc/GE2K-R369].
8. AM. COLL. OF OBSTETRICIANS & GYNECOLOGISTS, COMMITTEE OPINION: ACCESS TO
CONTRACEPTION (2015), https://www.acog.org/-/media/Committee-Opinions/Committee
-on-Health-Care-for-Underserved-Women/co615.pdf?dmc=1&ts=20171107T2231495401
[https://perma.cc/89DD-U764] [hereinafter ACCESS TO CONTRACEPTION].
9. See Elizabeth Nolan Brown, Why Americans Can’t Have Over-the-Counter Birth
Control Pills, REASON (Mar. 26, 2014, 4:31 PM), https://reason.com/archives/2014/03/26
/over-the-counter-birth-control-pills-us [https://perma.cc/NUA6-93HL].
10. Id.
11. Heather S. Dixon, Pelvic Exam Prerequisite to Hormonal Contraceptives: Unjustified
Infringement on Constitutional Rights, Governmental Coercion, and Bad Public Policy,
27 HARV. WOMEN’S L.J. 177, 196–97 (2004).
12. Id. at 178.
13. Unintended Pregnancy, supra note 5.
14. Id.
15. AM. COLL. OF OBSTETRICIANS & GYNECOLOGISTS, COMMITTEE OPINION: OVER-THE-
COUNTER ACCESS TO ORAL CONTRACEPTIVES 1 (2012), https://www.acog.org/-/media/Com
mittee-Opinions/Committee-on-Gynecologic-Practice/co544.pdf?dmc=1&ts=20160921T19
35019227 [https://perma.cc/6TTJ-V8AG] [hereinafter OVER-THE-COUNTER ACCESS].
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countries,16 and many of these countries allow access to non-pre-
scription contraception.17 These staggering numbers emphasize the
importance of providing access to much needed birth control. Cur-
rently, non-emergent contraception for women in the United States
is available only with a prescription and is often accompanied by
invasive and unnecessary physical examinations.18 The American
College of Obstetricians and Gynecologists (ACOG) released an opin-
ion supporting OTC contraception because it is low-risk, women can
self-screen for contraindications, and cervical screenings are not
related to implementation of a contraceptive regimen.19 Nonuse or
gaps in contraceptive use are commonly attributable to deficiencies
in access, but offering OTC availability could significantly remediate
our unintended pregnancy rates.20
Despite the need for ease of access to birth control, monetary
considerations have hindered the progression of OTC contraception.
The United States Preventive Services Task Force recommends that
women should undergo a cervical cancer screening once every three
years,21 but many physicians do not comply with this standard.22
The vast majority of doctors automatically test patients even if it is
not needed.23 Ironically, cervical cancer screenings and sexually
transmitted infection screenings have nothing to do with birth
control other than barricading access to it.24 However, doctors are
financially incentivized to continue holding women’s prescriptions
“hostage” and forcing unnecessary exams.25 Dr. Jeffrey Singer, an
16. Unintended Pregnancy, supra note 5.
17. Brown, supra note 9 (noting that out of 147 countries, 62 percent allowed access
to oral birth control without a prescription or screening, and eight percent allowed access
without a prescription but with a screening).
18. Id. (“A 2010 study found 33 percent of doctors always require a pelvic exam and
pap smear before prescribing hormonal contraception, and 44 percent regularly do. But
there’s no medical reason for linking these things. It’s like refusing to give someone
antibiotics unless they submit to a cholesterol screening.”).
19. OVER-THE-COUNTER ACCESS, supra note 15, at 3.
20. Id. at 1.
21. Final Update Summary, Cervical Cancer: Screening, U.S. PREVENTIVE SERVS.
TASK FORCE (Mar. 2012), https://www.uspreventiveservicestaskforce.org/Page/Document
/UpdateSummaryFinal/cervical-cancer-screening [https://perma.cc/Q7TL-CVMT].
22. Meredith Melnick, Are Doctors’ Exams a Barrier to Birth Control?, TIME (Dec. 6,
2010), http://healthland.time.com/2010/12/06/why-annual-exams-shouldnt-be-required
-to-get-birth-control-pills [https://perma.cc/H3WS-2BWW].
23. Id. (mentioning a survey from 2010 that showed that about 33 percent of phy-
sicians “always” require a pelvic exam before prescribing contraception, and 44 percent
“regularly” did).
24. OVER-THE-COUNTER ACCESS, supra note 15, at 3 (explaining that pelvic exami-
nations are not a necessity or requirement for prescribing oral contraception and “should
not be used as barriers to access.” ).
25. Brown, supra note 9.
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Arizona surgeon and adjunct scholar at the Cato Institute, described
these practices as “doctors extorting pay for a ‘permission slip’ to get
the same medication over and over again.”26 Disturbingly, physicians
are not the only parties that are profiting from mandatory prescrip-
tions. Pharmaceutical companies make more from prescription insur-
ance payments than they could if contraception was in a competitive
market.27 The FDA regulates prescription drugs, OTC medications,
and is responsible for switches from one to the other.28 An FDA
prescription drug switch can be initiated by the following parties: (1)
the FDA Commissioner; (2) any person who files a citizen petition; or
(3) the drug manufacturer.29 However, it is almost impossible for
anyone but the drug maker to have adequate funding and access to
the data required to implement a change.30 “Unsurprisingly, none of
the[se] sponsors who profit from keeping contraceptives Rx-only
want to challenge [the] status.” 31 Money simply outweighs practical
application, ethics, and patient care.
The need for change has given rise to trailblazers who are
testing alternative methods for OTC access to birth control. Because
change through the FDA is cumbersome and nearly impossible,
states are beginning to take matters into their own hands.32 Oregon
enacted a statute allowing women to receive oral contraception di-
rectly through a pharmacy without a doctor’s visit.33 Although the
statute still technically requires a prescription, a pharmacist is able
to write the required documentation after the patient has answered
a twenty-question self-assessment.34 A few months later, California
followed suit by adopting a similar law that offered not only “pills,
[but also] patches, injections and vaginal rings.” 35 While these laws
represent a dynamic change in women’s healthcare rights, they still
have issues and do not provide uniform access nationwide.
26. Id.
27. Id.
28. See Drugs, FOOD & DRUG ADMIN., https://www.fda.gov/Drugs [https://perma.cc
/LT79-6WCN].
29. Tummino v. Torti, 603 F. Supp. 2d 519, 525 (E.D.N.Y. 2009); see 21 U.S.C.A.
§§ 353(b)(3), 355(c)–(d) (Westlaw through Pub. L. No. 115-68).
30. Brown, supra note 9.
31. Id.
32. Pam Belluck, Birth Control Without Seeing a Doctor: Oregon Now, More States
Later, N.Y. TIMES (Jan. 4, 2016), http://www.nytimes.com/interactive/2016/01/04/health
/birth-control-oregon-contraception.html?_r=0 [https://perma.cc/4ABD-SV47].
33. 30 OR. REV. STAT. ANN. § 689.683 (West 2017).
34. See id. Belluck, supra note 32.
35. Soumya Karlamangla, What you need to know about California’s new birth
control law, L.A. TIMES (Apr. 8, 2016, 4:19 PM), http://www.latimes.com/local/lanow/la
-me-ln-birth-control-law-20160408-story.html [https://perma.cc/7PRN-ZPD2].
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This Article explores both medical and legal reasons as to why
OTC access to contraception is needed and justified. It also applies
current changes in the government and discusses how the repeal of
the Affordable Care Act (ACA) could substantially affect birth control.
Alternative and traditional options are presented and analyzed to
determine their viability.
Part I walks through the historical background of contraception
and the distribution practices over the last century. The history of
Plan B is also detailed in depth to offer insight into how the FDA
handled contraception switches in the past so that this can later be
compared to what may happen in the future.
Part II discusses the current unintentional pregnancy epidemic.
Specific data is offered to show why women who are young, minori-
ties, or poor are more susceptible to unintended pregnancies than
the rest of the population, and what impact OTC oral contraception
can have on these groups.
Part III walks through the requirements for pelvic examina-
tions and oral birth control and discusses why no correlation or
dependent relationship exists.
Part IV discusses some of the most prevalent concerns expressed
by opponents of over-the-counter oral contraception. Several studies
are provided to explain how these concerns are largely baseless.
Part V discusses how some physicians are exploiting require-
ments for financial benefits. The influence of pharmaceuticals on
physicians is also discussed.
Part VI looks at the how the FDA switch process, politics, and
religion can influence birth control distribution.
Part VII discusses how actions by the FDA and the prescription
requirement present Constitutional issues that impinge on the
rights of women.
Part VIII discusses several of the possible solutions that are
being proposed or utilized to solve contraception availability issues.
The final section provides a comprehensive conclusion explain-
ing why it is necessary to offer OTC oral contraception and how this
can be best accomplished.
I. BACKGROUND
Women’s access to oral contraception has faced extreme opposi-
tion that has persisted for decades.36 In 1873, Congress passed the
36. See Margaret Sanger and the Birth Control Movement, ISSUES & CONTROVERSIES
IN AM. HISTORY, http://ndhs.org/s/192/images/editor_documents/library/issues_and_con
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Comstock Law, an act labeling contraceptives as “obscene” material,
and outlawed the distribution of birth control through the postal
service and through interstate commerce.37 Aggressive raids of health-
care facilities, confiscation of diaphragms, banning of women’s litera-
ture discussing birth control, and formal charges against individuals
actively supporting contraception became the enforcement tools for
the new legislation.38 Hastily, twenty-four states followed suit and
enacted similar regulations that employed devastating penalties,
including a year-long imprisonment for any married couple using
contraception within the privacy of their own bedrooms.39 Due to these
harsh government restrictions, the “rhythm method, which involved
women having sex only during the safe days of their menstrual cycle
so that pregnancy would not occur,” was introduced and became the
predominant, and sometimes only, birth control option for women.40
Unfortunately, the difficulty of correctly utilizing this technique left
women with a better chance of winning Russian Roulette than stav-
ing off pregnancy.41 However, despite this high fallibility, the Catholic
Church, deviating from its staunch view against contraception,
sanctioned the use of this method as a natural form of birth control,
further expanding its use.42 Without options, women were forced to
desperately cling to this primitive and unreliable method for years
while contraception remained illegal.43
The next four decades played out like a game of tug-of-war
pitting birth control proponents against resistant states adhering to
outdated perceptions and ideals. One of the first instances of pro-
gression resulted from United States v. One Package, which made it
legal for physicians to receive contraception and information through
the mail unless prohibited by local law.44 The rationale was that
troversies_in_american_history_-_margaret_sanger_and_the_birth_control_movement.pdf
?sessionid=387b8c12-bcbd-45cb-a397-f95c6203313c&cc=1 [https://perma.cc/5EYS-Y2TY].
37. Id.
38. Id. (detailing that, in 1914, Margaret Sanger was indicted for nine violations of
the Comstock Law after including information about “birth control” in an issue of The
Women Rebel).
39. Carol Flora Brooks, The Early History of the Anti-Contraceptive Laws in Mas-
sachusetts and Connecticut, 18 AM. Q. 3, 4 (1966).
40. Roseann B. Termini & Miranda Lee, Sex, Politics, and Lessons Learned From
Plan B: A Review of the FDA’s Actions and Future Direction, 36 OKLA. CITY U. L. REV.
351, 352 (2011).
41. Fertility Awareness Methods, PLANNED PARENTHOOD, https://www.plannedparent
hood.org/learn/birth-control/fertility-awareness [https://perma.cc/MM7B-XD84] (reveal-
ing that 24 out of 100 people using the Rhythm Method incorrectly become pregnant).
42. See Rhythm Method, CASE W. RESERVE UNIV., https://case.edu/aff il/skuyhist
contraception/online-2012/Rhythm-method.html [https://perma.cc/9HJQ-X687] (prior to
1951, the only birth control option approved by Rome was abstinence).
43. Id.
44. United States v. One Package, 86 F.2d 737, 739–40 (2d Cir. 1936).
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physicians who lawfully use contraception to save the health of a
patient and not for unlawful abortions should not be held liable.45
Despite this minor headway, well into the 1960s, anti–birth control
laws preventing the sale and advertisement of contraception were
in full effect in nearly thirty states.46 In 1960, the FDA approved oral
contraception, but hauntingly, the after-effects of the Comstock Law
still loomed, leading to continued resistance.47 Eight states still pro-
hibited the sale of contraceptives despite FDA approval, widespread
acceptance, and mass support of the pill.48 Understanding the need
to force the hands of these defiant states, “[t]he United States
Supreme Court recognized a constitutional right to contraception in
1965 in the controversial Griswold v. Connecticut case involving a
physician who was arrested and prosecuted for providing birth control
to a married couple.” 49 Seven years later, the Supreme Court widened
its stance and extended these constitutional rights to unmarried
people, barring states from interfering in the distribution of birth
control to single individuals.50 The cause gained momentum and
garnered widespread support, including endorsements by President
Eisenhower, who felt that the government had no place meddling
with birth control, and President John F. Kennedy, who supported
federal backing of contraception for the poor.51
The growing acceptance of birth control led to millions of women
taking contraception, including almost eighty percent of American
Catholic women.52 Availability of highly effective contraception made
conception a choice rather than chance, made family planning pos-
sible, and resulted in sixty percent of women in their reproductive
45. Id. at 737.
46. Kirsten M.J. Thompson, A Brief History of Birth Control in the U.S., OUR BODIES
OURSELVES (Dec. 14, 2013), http://ourbodiesourselves.org/health-info/a-brief-history-of
-birth-control [https://perma.cc/SVX4-BLSB].
47. Sarah Glazer, Birth Control Choices: Do American women need better birth
control products?, CQ RESEARCHER, https://library.cqpress.com/cqresearcher/document
.php?id=cqressrre1994072903 [https://perma.cc/E848-KQSN] (explaining that, in 1957,
the FDA approved the pill for treatment of menstrual disorders. Three years later, the
pill was finally approved by the FDA for use as birth control).
48. Id.
49. Termini & Lee, supra note 40, at 352. See generally Griswold v. Connecticut, 381
U.S. 479 (1965) (ruling that prohibiting contraception for married couples is a constitu-
tional violation of the right to privacy).
50. See generally Eisenstadt v. Baird, 405 U.S. 438 (1972) (ruling that it was a
constitutional violation of the Equal Protection Clause to criminalize the provision of
contraception to unmarried people).
51. May, supra note 1 (revealing that President Eisenhower formally declared that
the government should not get involved with birth control).
52. Philip Pullella, U.S. Roman Catholic bishops fully support their church’s ban . . . ,
UPI ARCHIVES (Oct. 1, 1980), https://www.upi.com/Archives/1980/10/01/US-Roman-Catho
lic-bishops-fully-support-their-churchs-ban/1942339220800 [https://perma.cc/E2YD-6BBJ].
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years being employed.53 These effects were drastic improvements;
however, availability and affordability issues were pervasive.54 De-
spite President Eisenhower’s warning that government should take
its hands off birth control55 and the Supreme Court ruling that people
have the right “to be free from unwarranted governmental intrusion
into matters so fundamentally affecting a person as the decision
whether to bear or beget a child,” 56 the government, influenced by
political agendas, and the FDA remained highly involved in restrict-
ing access to birth control.57
Recently, a clash between the government, religious groups,
and women’s autonomy came to a head when emergency contracep-
tion was introduced.58 Many groups were staunchly opposed to Plan
B because they viewed the drug as “a pill for early abortion rather
than a pill for contraception.”59 The need to give more expedient access
led to a fight for OTC access that was long, arduous, and fraught
with corrupt political interference.60 Because Plan B is recommended
to be taken within twenty-four hours after unprotected intercourse,61
the prescription requirement was counterproductive and made it
impossible for some women to get the drug before this small window
closed. Understanding the need to break down this barrier, sixty-six
organizations pushed for OTC access to the drug.62 The process
started in 2001 but was delayed due to unresolved issues in the re-
quest.63 The actual manufacturer of the drug stepped in and submitted
a Supplemental New Drug Application (SNDA), again requesting
OTC authorization.64 In response to the SNDA, the FDA put together
53. Id.
54. Griswold v. Connecticut—The Impact of Legal Birth Control and the Challenges
that Remain, PLANNED PARENTHOOD (May 2015), https://plannedparenthood.org/up
loads/f iler_public/b6/7c/b67c1da4-c40a-4d0f-90af-952fdbf11fbf/factsheet_griswold_may
2015_r2.pdf [https://perma.cc/EFJ3-ZQ9S].
55. See May, supra note 1.
56. Eisenstadt v. Baird, 405 U.S. 438, 453 (1972).
57. Philip J. Hilts, Birth Control Backlash, N.Y. TIMES (Dec. 16, 1990), http://www
.nytimes.com/1990/12/16/magazine/birth-control-backlash.html?pagewanted=all&mcubz
=0 [https://perma.cc/H8M2-B475].
58. See generally Alex Kandalaft & Maddie Doucet Vicry, Seventeenth Annual Review
of Gender and Sexuality Law: Annual Review Article: Access to Contraception, 17 GEO.
J. GENDER & L. 55, 56 (2016).
59. Termini & Lee, supra note 40, at 355.
60. Id. at 352.
61. Id. at 353.
62. Tummino v. Torti, 603 F. Supp. 2d 519, 526 (E.D.N.Y. 2009) (explaining that 66 or-
ganizations of citizens and professionals petitioned the FDA for the OTC switch of Plan B
emergency contraception).
63. Id.
64. Id. at 523 (Women’s Capital Corporation would later become Barr Pharma-
ceuticals, Inc.).
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two committees to ensure that the drug’s safety and efficacy as an
OTC product fulfilled the requirements of 21 U.S.C. § 335.65 Evidence
suggests that many of the members of the committees “were not
qualified for the position and were placed only due to their conserva-
tive political views and connections.”66 Surprisingly, despite the inher-
ent bias that one might suspect from the composition of the advisory
board, they “overwhelmingly recommended” approval of Plan B as
an OTC product without age restrictions.67 “All twenty-eight panel
members voted that the drug had been proven to be ‘safe enough’ for
OTC use for all ages.” 68 Despite the extensive data and the recom-
mended approval by the expert panel, the FDA denied the applica-
tion based on a lack of research regarding adolescents.69 In response
to the rejection, Barr Pharmaceuticals resubmitted the application
restricting access to those under the age of sixteen.70 Again, the FDA
denied the application, and in response, the drug company filed a
third application restricting access to women who were seventeen
years of age or older and provided further data every time the FDA
requested information.71 Included in the submitted data were stud-
ies of adolescents as young as fourteen, but the FDA still rejected
the application, citing that it would be difficult for a pharmacist to
determine the age of a purchaser.72 Persistently, Barr Pharmaceu-
ticals filed another application which granted access to those eigh-
teen and older.73 On August 24, 2006, the FDA approved the switch
of Plan B to OTC for men and women over the age of eighteen.74 The
FDA based the restriction of access to minors on a lack of evidence,
but presumably, “one could assume there was no data or research
completed on male patients.” 75 Throughout the process, the FDA
thinly veiled their bias and underhanded motives by creating false
requirements for Barr Pharmaceuticals.76
The denials by the FDA, despite expert recommendations, mul-
tiple applications, and extensive supporting data, raised eyebrows
and led to an investigation by the U.S. Government Accountability
65. Termini & Lee, supra note 40, at 356.
66. Id.
67. Id.
68. Id.
69. Id. See also Tummino v. Torti, 603 F. Supp. 2d 519, 523–24 (E.D.N.Y. 2009).
70. Termini & Lee, supra note 40, at 356–57 (indicating that this change was based
on the FDA defining a pediatric-age group as birth to 16 years of age).
71. Id. at 357.
72. Id.
73. Id. See also Torti, 603 F. Supp. 2d at 536.
74. Termini & Lee, supra note 40, at 357.
75. Id.
76. Id. at 356–57.
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Office (GAO).77 The Center for Drug Evaluation and Research (CDER)
conducted an extensive review of the Plan B application and con-
cluded that, based on scientific evidence, the product was safe and
effective for use by adolescent females and that they understood that
the product did not protect against sexually transmitted diseases
and was not for routine use.78 Commissioner Margaret Hamburg
said that:
[S]he had “reviewed and thoughtfully considered the data, clinical
information, and analysis provided by CDER,” and she expressly
agreed that “there is adequate and reasonable, well-supported,
and science-based evidence that Plan B One-Step is safe and
effective and should be approved for nonprescription use for all
females of child-bearing potential.” 79
Despite the FDA being on board with Plan B’s approval, Kathleen
Sebelius, the Secretary of Health and Human Services, disagreed
with the decision and ordered the FDA to deny the application.80
“Some have opined that due to political pressure from high-ranking
officials, the decision to deny the application was made even before
the committees reviewed the research and data.” 81 It was an election
year and politicians knew that opposing Plan B would keep them on
the good side of religious groups that were opposed to making birth
control accessible to adolescents.82 Even President Bush endorsed
this decision,83 despite the decision’s “departure from agency prac-
tice.” 84 Sebelius argued that girls can reach menarche by age eleven
and that there was not enough evidence to prove that these girls
could understand how to safely use the product.85 Ironically, the
FDA had previously waived the requirement that the studies had to
include girls between the ages of eleven and thirteen.86 Thus, Sebelius
made the FDA deny the Plan B application “because it lacked data
that the FDA itself had told the sponsor it did not have to provide.”87
The Editor-in-Chief of the New England Journal of Medicine opined
that Sebelius’s decisions were not based on science, but rather were
77. Id. at 357.
78. Tummino v. Hamburg, 936 F. Supp. 2d 162, 166–67 (E.D.N.Y. 2013).
79. Id. at 167.
80. Id. (explaining the President endorsed Secretary Sebelius’s denial for Plan B).
81. Termini & Lee, supra note 40, at 358.
82. See Tummino v. Hamburg, CTR. FOR REPROD. RIGHTS (Aug. 13, 2013), https://
www.reproductiverights.org/case/tummino-v-hamburg [https://perma.cc/5XS4-9V4A].
83. Hamburg, 936 F. Supp. 2d at 167.
84. Id. at 170.
85. Id. at 172.
86. Id. at 171.
87. Id.
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politically motivated.88 At the prompting of members of Congress,
the Government Accountability Office conducted an investigation
and found that the FDA’s actions went against their customary prac-
tices and that behavior of FDA officials deviated from the norms,
even going so far as officials refusing to place their names on the
“not approvable letter[s].” 89
Even after the 100 plus years that the fight over birth control
has carried on, ease of access still eludes us. Impediments such as
required gynecological examinations and prescription-only access
unnecessarily bar some women from obtaining much needed birth
control.90 Additionally, the volatile state of the government leaves
many women concerned about their health and the impacts of a pos-
sible Affordable Care Act repeal.91 “The most vulnerable regulation
is the requirement that health insurers cover contraception for all
women without a co-payment.” 92 A total repeal would cancel out this
privilege and “leave [roughly] 22 million people without coverage,
many of them women” from utilizing this benefit specifically for ob-
taining birth control.93 Offering over-the-counter access would break
down barriers and restrict flippant decisions from having devastat-
ing consequences on women’s health.94 However, history has a strange
way of repeating itself, and the plight of Plan B shows that a possi-
ble FDA switch may be an uphill battle against strong opposition.95
II. THE UNINTENDED PREGNANCY EPIDEMIC
Unintended pregnancy is “a major public health problem in the
United States” that is perpetuated by the lack of access to contra-
ception.96 Nationally, approximately fifty percent of pregnancies are
unplanned, of which only five percent are attributable to women
who use contraception properly.97 These pregnancy rates, along with
abortions, are higher in our country than in most other developed
88. Id. at 170–71 (“It cannot be based on issues of safety, since a 12-year-old can
purchase a lethal does of acetaminophen in any pharmacy for about $11,” but the only
adverse effects of levonorgestrel are nausea and delay of menses).
89. Termini & Lee, supra note 40, at 358.
90. See Brown, supra note 9.
91. See Margot Sanger-Katz, No, Birth Control Coverage Won’t Go Away, N.Y. TIMES
(Nov. 11, 2016), https://www.nytimes.com/2016/11/11/upshot/no-birth-control-coverage
-wont-go-away.html?_r=0 [https://perma.cc/H7AN-9498].
92. Id.
93. Id.
94. See Brown, supra note 9.
95. See Termini & Lee, supra note 40, at 364–66.
96. OVER-THE-COUNTER ACCESS, supra note 15, at 1.
97. Unintended Pregnancy, supra note 5.
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countries.98 Women who are poor, aged eighteen to twenty-four, or
who are minorities, are at a much higher risk of having an unin-
tended pregnancy and account for the majority of the cases each
year.99 Statistics show that contraception is effective at avoiding
these devastating circumstances and that, by creating solutions that
are tailored to reach these highly susceptible demographics, this
epidemic can be combated.100 Preventing unintended pregnancies
requires getting to the root of the problem and addressing the most
common reasons why they occur: access and cost.101 These affected
groups often do not have the resources to pay for unnecessary test-
ing, physician visits, or for the extensive medical costs associated
with pregnancy and child rearing.102 The consequence, birth rates
increase and the adverse effects of unintended births, such as de-
layed prenatal care, premature birth, and negative physical and
mental health for children, exacerbate our national healthcare costs,
resulting in cumulative, yearly government expenditures of over
twenty-one billion dollars.103 A 2004 survey showed that “47% of
uninsured women and 40% of low-income women . . . not using
[contraception] . . . would [begin] using [it] if [it] were available from
pharmacies without a prescription,”104 showing that removing costly
barriers would have a substantial impact.
Offering OTC access also provides an avenue for young women
to acquire much needed protection and prevents lapses in use.105
Often, young women do not start birth control because they are fear-
ful about disclosing their sexual activity to a parent or guardian.106
Too much focus is placed on abstinence-only education for young
people despite research showing “its ineffectiveness in increasing
age of sexual debut and decreasing number of partners and other
risky behavior.”107 Adequate contraception is the only effective way
to lower teen pregnancy and allowing discrete OTC access would curb
the issue.108 Additionally, access to multiple packs of oral contraception
effectively results in better continuation of preventative regimens.109
98. See ACCESS TO CONTRACEPTION, supra note 8.
99. See Unintended Pregnancy, supra note 5.
100. See ACCESS TO CONTRACEPTION, supra note 8.
101. See OVER-THE-COUNTER ACCESS, supra note 15, at 1.
102. See ACCESS TO CONTRACEPTION, supra note 8.
103. Unintended Pregnancy, supra note 5 (detailing that in 2010, total public expen-
ditures for unintentional pregnancies amounted to approximately $21 billion.)
104. OVER-THE-COUNTER ACCESS, supra note 15.
105. Id. at 2–3.
106. See Belluck, infra note 330.
107. ACCESS TO CONTRACEPTION, supra note 8.
108. Id. See generally Belluck, infra note 330.
109. ACCESS TO CONTRACEPTION, supra note 8.
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The result is fewer gaps in coverage and lessened failure rates at-
tributable to treatment inconsistency.
III. MISSED CONNECTIONS: WHY PELVIC EXAMS AND
CONTRACEPTIVES DO NOT CORRELATE
Preventative gynecological testing and physician check-ups
conducted in accordance with recommended standards of care are
very important for early detection of serious disorders and disease
in women,110 but they should not be a requirement for birth control.
Outdated methodology lumps pelvic examinations and birth control
together simply because both relate to women’s reproductive health,
but new developments show that this dependent association is
flawed.111 Government and expert recommendations, backed by data
and research, highlight the lack of correlation between pelvic exami-
nations and the administration of birth control, but thus far have
been taken with a grain of salt.112 Perpetuating the issue, physicians
are financially incentivized to continue administering needless health-
care and are insulated from liability by the prescription requirement
and outmoded perceptions about women’s health.113 Requiring
yearly pelvic examinations and testing as prerequisites for prescrib-
ing birth control is grossly unnecessary and wholly deceitful.
Many physicians, without consideration of an individual pa-
tient’s medical history, regularly require yearly pap smears and
pelvic exams for a hormonal contraception prescription despite the
present standards and there being no medical reason for linking the
two.114 The government currently recommends that, starting at age
twenty-one, women should get a pap smear every three years.115
After the age of thirty, a woman can switch to a combination pap
smear and human papillomavirus test that only needs to be admin-
istered once every five years.116 The National Ambulatory Medical
Care Survey reported that 62.8 million pelvic examinations were
administered in 2010, often regardless of whether or not the patient
110. See Melnick, supra note 22.
111. Id.
112. Brown, supra note 9.
113. Id.
114. Id. (“A 2010 study found 33 percent of doctors always require a pelvic exam and
pap smear before prescribing hormonal contraception, and 44 percent regularly do. But
there’s no medical reason for linking these things. It’s like refusing to give someone
antibiotics unless they submit to a cholesterol screening.”).
115. See Women: Stay Healthy at Any Age, AGENCY FOR HEALTHCARE RESEARCH &
QUALITY (May 2014), http://www.ahrq.gov/patients-consumers/prevention/lifestyle/healthy
-women.html [https://perma.cc/8XTY-VC6K].
116. See id.
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was asymptomatic.117 The dangers associated with these frivolous
practices are not merely that of inconvenience; an expert panel “not
only found no benefit from the annual pelvic exam, they found that
it often causes discomfort and distress” and can lead to unnecessary
surgery.118 An independent government task force reached a similar
conclusion, determining that there was not enough scientific evidence
to prove that these exams were needed.119 Despite current evidence
being “lacking and of poor quality”120 and not providing sound medi-
cal reasons for these exams, physicians continue to aggressively test
asymptomatic patients anyway.121
IV. CONCERNS ABOUT OTC ACCESS TO THE PILL
Access to contraception is a point of contention that places po-
litical, medical, religious and many other views at odds with each
other. Motivation aside, there are several primary concerns that
opponents of OTC access to birth control often assert: (1) safety; (2)
screening for contraindications; (3) adherence and continuation; (4)
use of preventative services; and (5) cost.122 The ACOG, an organiza-
tion made up of 58,000 board-certified gynecologists, released an
opinion that addressed each of these concerns.123 They concluded
that “[w]eighing the risks versus the benefits based on currently
available data, OCs should be available over-the-counter.”124
A. Safety
Every drug or intervention has some possibility of harm,125 but
the risk associated with oral contraception is so minuscule that OTC
117. Draft Recommendation Statement: Gynecological Conditions: Periodic Screening
with the Pelvic Examination, U.S. PREVENTIVE SERVS. TASK FORCE (June 2016),
https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation
-statement157/gynecological-conditions-screening-with-the-pelvic-examination [https://
perma.cc/L2YQ-4MRE] [hereinafter Gynecological Conditions].
118. Howard LeWine, Expert panel says healthy women don’t need yearly pelvic exam,
HARV. HEALTH PUBL’NS (July 2, 2014), http://www.health.harvard.edu/blog/expert-panel
-says-healthy-women-don’t-need-yearly-pelvic-exam-201407027250 [https://perma.cc
/9ENX-6Q5B].
119. Linda Carroll, It’s unclear whether yearly pelvic exam is necessary, task force says,
TODAY (June 29, 2016, 7:30 AM), http://www.today.com/health/it-s-unclear-whether
-yearly-pelvic-exam-necessary-task-force-t100354 [https://perma.cc/JB6N-GEQ5].
120. Gynecological Conditions, supra note 117.
121. Id.
122. See OVER-THE-COUNTER ACCESS, supra note 15, at 1–3.
123. See generally OVER-THE-COUNTER ACCESS, supra note 15; see also About Us, AM.
CONG. OF OBSTETRICIANS & GYNECOLOGISTS, https://www.acog.org/About-ACOG/About
-Us [https://perma.cc/S9MJ-X3YG].
124. OVER-THE-COUNTER ACCESS, supra note 15, at 3.
125. Id. at 1.
<
WILLIAM  & MARY JOURNAL OF WOMEN AND THE LAW           [  V    o l. 24:295
access should be approved by the FDA. Everyday drugs such as aspi-
rin have negative effects, including gastrointestinal bleeding, even
in small doses.126 Another example, Tylenol, the most popular OTC
pain reliever in the world, “is the leading cause of acute liver failure
in the U.S., and the drug in some cases [leads] to fatalities.”127 Each
year, acetaminophen, the active ingredient in Tylenol—which sends
approximately 60,000 people to the hospital—“accounts for more
than 100,000 [visits] to poison [control] centers,” and causes hun-
dreds of deaths.128 Despite these effects, the FDA allows OTC access
with only a small warning on the package.129 In contrast, you cannot
overdose on birth control pills, “and you’re very unlikely to experi-
ence other serious adverse effects,”130 but you cannot acquire contra-
ception without physician visits, invasive testing and a prescription.
In an effort to detract from realities such as these, opponents point
to a dangerously increased incidence of venous thromboembolism
from oral birth control;131 however, in actuality, the rate of venous
thromboembolism for oral birth control users is “extremely low”
especially when compared to the greater risk during pregnancy or
in the postpartum period.132 Because oral contraception is very low-
risk, it should be afforded the same OTC classification as other
drugs, such as Tylenol, that have far greater adverse effects.
B. Contraindication Screening
Despite the safety of OC use, many opponents are still con-
cerned about potential harm for women with contraindications.133
However, studies have shown that contraindications can be detected
by women who self-screen.134 In one study, women were asked to do
self-assessments of contraindications and the results were then
compared to assessments by healthcare providers.135 Out of 399 par-
ticipants, only seven self-screening assessments were not in line with
the clinical assessment.136 Similar results were found in another
126. Id.
127. Tylenol, DRUGWATCH (Mar. 7, 2016), https://www.drugwatch.com/tylenol [https://
perma.cc/ZE4Z-RNYJ].
128. Id.
129. Id.
130. Brown, supra note 9.
131. OVER-THE-COUNTER ACCESS, supra note 15, at 1.
132. Rates of venous thromboembolism for OC users is (3–10.22/10,000 women-years)
while rates are higher during pregnancy (5–20/10,000 women-years) and the postpartum
period (40–65/10,000 women-years). Id. at 1–2.
133. Id. at 2.
134. Id.
135. Id.
136. Id. (showing that agreement on medical eligibility criteria among women and
healthcare providers was greater than 90 percent).
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study conducted on 1,271 women.137 Surprisingly, “[b]oth studies
showed that in cases of discrepancy, women were more likely to re-
port contraindications than were health care providers.”138 Another
study, conducted in the United Kingdom, “replicated the findings that
women take a more conservative approach compared with clinicians
and also demonstrated that none of the 328 women studied would
have incorrectly used OCs based on self-screening.”139 Thus, not only
is self-screening highly effective at detecting contraindications, but
the women who are self-screening are more sensitive to possible
issues than their physicians. Overall, the ability of women to accu-
rately self-screen eliminates the need for physician interaction prior
to obtaining birth control.
C. Adherence and Continuation
Other concerns include the idea that women might have more
issues with continuing to routinely take birth control if they utilize
oral contraception instead of long-acting methods such as IUDs.140
Many women are not currently utilizing birth control at all, which
presents a larger problem than there being some compliance issues.141
Whether or not a woman chooses long-term or short-term birth con-
trol, at the end of the day, contraception is being taken and unin-
tended pregnancies are being limited. “In one study, 68% of . . . women
who might avail themselves to over-the-counter OCs reported not
currently using any contraceptive method.”142 The focus should not
be on the method, but rather on how utilization of birth control, in
general, can be increased.
Despite concerns, the theory that OTC access results in poor
continuation is not supported by recent evidence. A study evaluating
1,000 women showed that there were higher rates of continuation
for those who obtained OTC birth control versus in a clinic.143 Addi-
tionally, data shows that access to multiple pill packs at a time
results in better adherence and continuation rates,144 but insurance
137. OVER-THE-COUNTER ACCESS, supra note 15, at 2.
138. Id.
139. Id.
140. See Amanda MacMillan, Study: IUDs, Implants vastly more effective than the pill,
CNN (May 23, 2012, 5:21 PM), http://www.cnn.com/2012/05/23/health/iuds-implants
-versus-pill-birth-control/index.html [https://perma.cc/DBD8-9TJQ].
141. See Fact Sheet: Contraceptive Use in the United States, GUTTMACHER INST. (Sept.
2016), https://www.guttmacher.org/fact-sheet/contraceptive-use-united-states [https://
perma.cc/9795-3UQE].
142. OVER-THE-COUNTER ACCESS, supra note 15, at 2.
143. Id.
144. Id. at 2–3. See also ACCESS TO CONTRACEPTION, supra note 8, at 3.
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limits the amount of products that can be dispensed.145 In fact,
seventy-three percent of women cannot get more than one month of
birth control at a time, despite there being an issue with women ac-
quiring refills on a timely basis.146 By offering OTC access, overall
usage rates will increase, women will have access to multiple months
of products, and continuity will improve.
D. Preventative Services
Another concern is that women will stop going for preventive
screenings and services if they can get OTC birth control.147 Annual
health visits are important to a woman’s health, but holding birth
control hostage to force women into succumbing to unrelated medi-
cal care is not an appropriate justification. In accordance, ACOG
recognized that “cervical cancer screening or sexually transmitted
infection (STI) screening is not required for initiating OC use and
should not be used as barriers to access.”148 A study in 2012 showed
that there were no significant differences in the screening habits of
women who received prescription birth control and women who
received OTC oral contraception, showing that birth control does not
have a significant effect on the utilization of preventative services.149
Scheduling issues aside, the actual screenings are unreliable
and do not justify the continued push for these services.150 The
regular pelvic examination screenings for Chlamydia, cervical can-
cer, and early detection of ovarian cancer produce poor results and
dissuade some women from seeking treatment.151 New advance-
ments provide more effective screening alternatives that do not
require invasive visits.152 By utilizing these new methods of screen-
ing, compliance rates will increase.
1. Chlamydia Screening
Chlamydia is a very common sexually transmitted bacterial
infection that, if left untreated, “can cause . . . permanent damage
145. ACCESS TO CONTRACEPTION, supra note 8, at 3.
146. Id.
147. OVER-THE-COUNTER ACCESS, supra note 15, at 3.
148. Id.
149. See id.
150. Carolyn L. Westhoff, Heidi E. Jones, & Maryam Guiahi, Do New Guidelines and
Technology Make the Routine Pelvic Examination Obsolete?, 20 J. WOMEN’S HEALTH 5,
6–8 (2011).
151. Id. at 5, 7–8.
152. Id. at 6–8.
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to a woman’s reproductive system.”153 It may be difficult or impossi-
ble for women who experience these horrific effects to get pregnant
and, if they do, may cause a potentially fatal ectopic pregnancy.154 Of
the estimated three million people who contract Chlamydia each year,
the highest incidence of the infection occurs in women under the age
of twenty-five.155 Despite the large concentration within this age
bracket, testing rates remain low among young women.156 Currently,
“avoidance of [the pelvic] examination may be a reason that only
about 50% of insured women [under 26 years old] undergo recom-
mended annual screening for Chlamydia.”157 New advancements
permit detection of Chlamydia through urine and self-collected
vaginal swabbing.158 This innovative technology is highly sensitive,
obviates the need for pelvic examinations to screen for infection, and
is vastly “more cost-effective and cost-saving than clinician-collected
specimens during . . . pelvic examination[s].”159 By supplementing
these less expensive and intrusive options for the pelvic examina-
tion, more women will engage in early screening that will help
prevent infertility and permanent gynecological harm.
2. Cervical Cancer Screening
Abnormal cervical screenings require frequent follow up care,
but women with normal results do not need annual testing and can
follow the currently recommended three- to five-year protocol.160 The
utilization of a pelvic examination for the detection of cancer has
been abandoned because bimanual examinations have poor and
ineffective results of early detection and alternative methods are
consistent and preferred.161 “Annual pelvic exams for screening
purposes (as opposed to diagnostic purposes, as in the case of a
patient presenting physical symptoms) carry a high risk of false
positives, which can lead to expensive and sometimes risky unneces-
sary biopsies or surgeries.”162 In essence, over-screening can actually
153. Chlamydia—CDC Fact Sheet, CTRS. FOR DISEASE CONTROL (May 19, 2016), http://
www.cdc.gov/std/chlamydia/stdfact-chlamydia.htm [https://perma.cc/679F-HKNF].
154. Id.
155. Chlamydia—CDC Fact Sheet (Detailed), CTRS. FOR DISEASE CONTROL, https://
www.cdc.gov/std/chlamydia/stdfact-chlamydia-detailed.htm [https://perma.cc/BQ2A-97H3].
156. Id.
157. Westhoff et al., supra note 150, at 7.
158. Id. at 6.
159. Id.
160. Id. at 6–7.
161. Id. at 7.
162. Christina Cauterucci, If You’re a Healthy Woman, There’s No Evidence You Need
an Annual Pelvic Exam, SLATE (June 29, 2016, 1:33 PM), http://www.slate.com/blogs
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produce more harm than good.163 In recognition of evidence such as
this, the FDA, World Health Organization (WHO), ACOG, and
Planned Parenthood Federation of America (PPFA) explicitly stipu-
late that a pelvic examination is not required or necessary for the
prescription of hormonal contraception.164 While appropriate and
consistent testing for cervical cancer is important, the other “justi-
fications” are largely unfounded and, in the case of birth control,
completely unnecessary.165
3. Early Detection of Ovarian Cancer
The bimanual pelvic examination is a poor detector of early stages
of ovarian cancer, rendering it an ineffective method for preventa-
tive treatment.166 Studies comparing the United States and the
United Kingdom demonstrate that there is no difference in the
diagnosis of Stage I ovarian cancer when the bimanual pelvic exami-
nation is not performed.167 The examination has “poor sensitivity
and specificity for the detection of ovarian cancer,” rendering it
obsolete.168 Recently, a trial by the National Cancer Institute elimi-
nated these practices after data showed that “no ovarian cancers
had been [found by] this modality alone.”169 Additionally, the U.S.
Preventive Services Task Force found that this testing does not re-
sult in a decrease in mortality or any preventative benefits,170 and
along with the American Cancer Society and ACOG, recommend
forgoing this method.171
E. Cost
Many groups are concerned that offering OTC birth control will
drive up prices and affect insurance coverage for certain types of
contraception.172 This is not the case; it will actually provide a more
/xx_factor/2016/06/29/annual_pelvic_exams_are_not_necessary_for_healthy_women_u
_s_panel_says.html [https://perma.cc/GN9K-XVFF].
163. Cf. Westhoff et al., supra note 150, at 5–8.
164. Id. at 7 (confirming that these recommendations are applicable for asymptomatic
patients).
165. OVER-THE-COUNTER ACCESS, supra note 15, at 3.
166. Westhoff et al., supra note 150, at 7.
167. Id. (explaining that these recommendations are applicable for asymptomatic
patients).
168. Id.
169. Id.
170. Cauterucci, supra note 162.
171. Westhoff et al., supra note 150, at 7.
172. Sneha Barot, Moving Oral Contraceptives to Over-the-Counter Status: Policy
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affordable option for many women.173 Currently, birth control is
covered fully under the Affordable Care Act and also under Medi-
caid.174 However, this is likely to change under President Donald
Trump, who has pushed to quickly repeal the Affordable Care Act.175
Under the ACA, individuals who fall 138% below the national poverty
level qualify for Medicaid.176 Outside of Medicaid, only women who
are insured gain access to free birth control, while uninsured women
are unaffected.177 This means that any woman who is not insured or
that does not fall 138% below the federal poverty limit is left without
access to free care. Because of the prescription requirement, women
falling in this gap are not only paying for their birth control, but
they are also paying for costly health visits, testing and even unnec-
essary surgical procedures.178 “More than twenty percent of public
health care providers report that most of their clients seeking con-
traception have difficulty paying for their visit.”179 Insured and
uninsured low-income women are presented with even more barriers
such as transportation difficulties, especially in rural areas where
offices can be far away, or the inability to go to appointments “dur-
ing business hours because of their work schedules.”180 Therefore,
these additional services and barriers are more cost prohibitive than
the birth control itself.
Offering OTC oral contraception would foster market competi-
tion that would drive down the price of birth control.181 Despite the
low manufacturing cost for birth control, drug makers charge astro-
nomical prices because the costs are not shouldered by the consumer,
but are instead passed on to insurance companies that are required
to foot the bill.182 There are many pharmaceutical companies pro-
ducing oral contraception, and in an OTC model, these drug makers
Versus Politics, 18 GUTTMACHER POL’Y REV. 85, 87 (2015), https://www.guttmacher.org
/sites/default/f iles/article_files/gpr1808515.pdf [https://perma.cc/A9LC-G9HK].
173. Manning, infra note 181.
174. REPRODUCTIVE RIGHTS & HEALTH: THE AFFORDABLE CARE ACT’S BIRTH CONTROL
BENEFIT IS WORKING FOR WOMEN, NAT’L WOMEN’S LAW CTR. 1, 1 (Dec. 2016), https://
nwlc.org /resources/the-affordable-care-acts-birth-control-benefit-is-working-for-women
[https://perma.cc/FX34-JBVD].
175. Haberman & Pear, supra note 3.
176. Kandalaft & Vicry, supra note 58, at 79.
177. Id. at 78.
178. Cf. Westhoff et al., supra note 150 and Cauterucci, supra note 162.
179. Kandalaft & Vicry, supra note 58, at 78.
180. Id.
181. Hadley Heath Manning, Planned Parenthood Misunderstands The Costs Of Birth
Control, And The Concept Of Real Choice, FORBES (Oct. 25, 2014, 9:38 AM), http://www
.forbes.com/sites/theapothecary/2014/10/25/planned-parenthood-misunderstands-the
-costs-of-birth-control-and-the-concept-of-real-choice/#292a8cf819fb [https://perma
.cc/E8BL-6B2P].
182. Id.
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would be forced to offer competitive pricing.183 “This means that
neither women nor insurance policy holders in general would have
to pay thousands of dollars each year for what should be an inexpen-
sive product.”184
V. HEALTH PROVIDER EXPLOITATION
Making unsubstantiated healthcare a contingency for acquiring
birth control makes treatment more about money and less about a
woman’s autonomy and sound medical practice. If a man were to
make an appointment to get his blood pressure medication refilled,
and the doctor always conditioned the prescription on the patient
undergoing an unneeded rectal exam, this would be considered
outrageous. Because the resounding consensus by many groups—
such as the FDA, WHO, ACOG, and PPFA—is that a pelvic exam is
unnecessary for the prescription of hormonal contraception, this
requirement is, in effect, equally nonsensical and should be consid-
ered a fraudulent medical practice.185 Unfortunately, it is too easy
for physicians to support these practices because not doing so would
chip away at their profits.186 Allowing OTC access removes the
temptation to administer needless healthcare and places a greater
emphasis on providing women with treatment that is individualized
to their needs.
A. Third-Party Influence
Exchanges between physicians, drug makers, and medical device
companies raise questions about whether perks and benefits are
influencing how doctors are treating patients. Despite the Sunshine
Act, companies are shelling out billions of dollars to physicians and
hospitals each year.187 In 2015 alone, 7.52 billion dollars were paid
by the industry.188 Doctors are being remunerated for many things
that one might expect, such as meals, travel, and speeches, but they
183. Id.
184. Id.
185. Westhoff et al., supra note 150, at 6.
186. Is the Routine Pelvic Examination Obsolete?, COLUM. UNIV. (Feb. 25, 2011),
https://www.mailman.columbia.edu/public-health-now/news/routine-pelvic-examination
-obsolete [https://perma.cc/UJ2K-2Z33] [hereinafter Routine Pelvic Examination]
(explaining that pelvic exams are a large factor in healthcare costs. Thus, eliminating
them would cut the amount of money received by doctors).
187. Sy Mukherjee, Drug and Medical Device Companies Shelled Out $7.5 Billion to
Docs and Hospitals in 2015, FORTUNE (July 5, 2016), http://fortune.com/2016/07/05/drug
-companies-paid-doctors-billions [https://perma.cc/KF5M-X9KB].
188. Id.
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are also being compensated with things that you might not expect,
such as research and continuing medical education (CME).189 In
order to maintain an active medical license, physicians must com-
plete CMEs that are intended to apprise them of new science.190
Many CMEs are conducted in desirable locations with lavish accom-
modations and are funded by drug and medical device companies
who reap financial benefits from frivolous medical procedures.191
The result is that doctors are receiving yearly medical education
that is biased and developed with the ulterior motive of pushing
more unneeded services, and the process is highly successful.192 For
instance, a ProPublica analysis concluded that doctors who were given
more money “were also more likely to prescribe brand name, rather
than cheaper generic, drugs. And the percentage of brand name
prescriptions tends to increase with the amount of money received.”193
OTC access would cut down on these practices by reducing the
amount of opportunities that physicians have to carry out this un-
ethical behavior.
B. Physician Motivation
Office visits and testing add up to increased profits, and, because
pap smears and contraception have been a package deal for so long,
they are ritualistic and many physicians do not want to stop admin-
istering these tests.194 Not only are women having to schedule yearly
gynecological appointments for the sole purpose of getting a birth
control prescription, but, regardless of their personal medical needs
or issues, are being forced to undergo too frequent and often unneeded
examinations.195 “A 2010 study found 33 percent of doctors always
require a pelvic exam and pap smear before prescribing hormonal
contraception, and 44 percent regularly do.”196 While this may seem
harmless, these needless pelvic exams consume precious time dur-
ing wellness visits that could be better utilized, can prevent women
from seeking routine care because they are “notoriously uncomfort-
able and . . . disliked,” and can lead to unnecessary surgeries.197 For
189. Id.
190. Stephanie Mencimer, Holding Birth Control Hostage, MOTHER JONES (Apr. 30,
2012, 10:00 AM), http://www.motherjones.com/politics/2012/04/doctors-holding-birth
-control-hostage [https://perma.cc/9FFM-4M6Z].
191. AAFP CME by Location, AAFP, http://aafp.org/cme/browse/all-locations.html
[https://perma.cc/LV5A-DY75]; Mencimer, supra note 190.
192. See, e.g., Mukherjee, supra note 187.
193. Id.
194. LeWine, supra note 118.
195. Brown, supra note 9.
196. Id.
197. Routine Pelvic Examination, supra note 186.
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example, U.S. rates of hysterectomies and ovarian cystectomies “are
more than [double that of] . . . European countries, where . . . pelvic
examination is limited to symptomatic [patients].”198 Increasingly,
it is being recognized “that more services do not always lead to
improved health outcomes and that often the opposite is true: that
more services are associated with worse heath [sic] outcomes.”199
Despite these negative effects, physicians are not willing to discon-
tinue these practices and embrace new procedures because they are
being incentivized to not change.200 Medical procedures are lucrative
and not testing asymptomatic patients chips away at unnecessary
surgeries and, ultimately, extra revenue streams.201 Doctors want
to keep their offices booming and money in their pockets and can do
so by pressing for additional visits, testing, and surgeries.202 At the
end of the day, a precarious situation is created where physicians
profit at the expense of patients, but OTC access can change this by
stopping needless visits.203
C. Healthcare Fraud
By conducting indiscriminate and unnecessary pelvic screen-
ings, healthcare providers are in direct conflict with the directives
of the Department of Justice and Centers for Medicare and Medicaid
Services (CMS) and are adding to the fraud epidemic.204 Administer-
ing superfluous healthcare is not a small issue, but rather, a prob-
lem of epic proportions. It is estimated that unnecessary healthcare
totals at least $158 billion a year.205 Through the False Claims Act,
the Justice Department and the CMS recovered over $16.2 billion
dollars in healthcare fraud cases in only six years.206 To compound
this rampant exploitation of medical services, the Department of Jus-
tice made it their mission to be “committed to ensuring that labora-
tory tests, including drug and genetic tests, are ordered based on
each patient’s medical needs and not just to increase physician and
198. Id.
199. Id. (quoting Dr. Carolyn Westhoff).
200. Cf. id.
201. Brown, supra note 9.
202. Cf. Routine Pelvic Examination, supra note 186.
203. Cf. Brown, supra note 9.
204. Millennium Health, infra note 206.
205. Health Policy Brief, HEALTHAFFAIRS (Dec. 13, 2012), http://healthaffairs.org/health
policybriefs/brief_pdfs/healthpolicybrief [https://perma.cc/9YJQ-NF3W].
206. Press Release, Dep’t of Justice, Millennium Health Agrees to Pay $256 Million to
Resolve Allegations of Unnecessary Drug and Genetic Testing and Illegal Remuneration
to Physicians (Oct. 19, 2015), https://www.justice.gov/opa/pr/millennium-health-agrees-pay
-256-million-resolve-allegations-unnecessary-drug-and-genetic [https://perma.cc/E2TF
-H3KB] [hereinafter Millennium Health]. See generally 31 U.S.C.A. §§ 3729–3733 (2009).
2
SEX, DRUGS, TRUMP AND BIRTH CONTROL 319
laboratory profits.” 207 Additionally, the head of the Justice Depart-
ment’s Civil Division, Principal Deputy Assistant Attorney General
Benjamin C. Mizer, stated that the Department “will not tolerate
practices such as the ordering of excessive, non-patient specific tests
and the provision of inducements to physicians that lead to unneces-
sary costs being imposed upon our nation’s health care programs.”208
Despite this stance, this is precisely what the prescription require-
ment encourages. When physicians conduct pelvic examinations and
screenings on asymptomatic patients against government and
medical recommendations, they are administering fraudulent medi-
cal care that is in violation of the False Claims Act.209
VI. OTHER HINDRANCES STALLING THE
PROGRESSION OF BIRTH CONTROL
Safety, efficiency, reasonable access, objectivity, and public wel-
fare are all elements that should be paramount when evaluating and
determining the status of readily used drugs,210 but these are not
considerations that are driving the availability of birth control.
Political, religious, and monetary motives are at the forefront of a
divisive movement restricting OTC access to contraception, and the
FDA does not have the ability to combat the problem.211 This is
mostly attributable to the prescription-to-OTC switch process which
is fatally flawed, allowing self-interested parties to block access to
OTC oral contraception.212
Political intrusion into contraception matters has slowed and,
at times, halted the switch process.213 “When Plan B emergency con-
traception was being considered for [OTC] sale, politicians of both
parties intervened in the process, slowing it down and imposing an
unreasonable age restriction, one that was lifted only after a 10-year
legal battle.”214 History often repeats itself, and companies may hesi-
tate to push for OTC oral contraception because of the potential for
207. Millennium Health, supra note 206.
208. Id.
209. See 31 U.S.C.A. § 3729 (2009).
210. Cf. Daniel Grossman, Birth control pills should not be prescription-only, L.A.
TIMES (June 19, 2015, 5:00 AM), http://www.latimes.com/opinion/op-ed/la-oe-grossman
-otc-birth-control-pills-20150619-story.html [https://perma.cc/B273-UE7E].
211. Tasha M. LaSpina et al., Eleventh Annual Review of Gender and Sexuality Law:
Health Care Law Chapter: Access to Contraception, 11 GEO. J. GENDER & L. 371, 404–06
(2010). See generally Grossman, supra note 210; Mencimer, supra note 190.
212. LaSpina et al., supra note 211, at 405–06. See generally Grossman, supra note
210; Mencimer, supra note 190.
213. LaSpina et al., supra note 211, at 395.
214. Grossman, supra note 210.
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political interference that could result in exorbitant costs and uncer-
tainties during the FDA approval process.215
Many religious organizations vehemently oppose contraception
and do not want to expand availability.216 Refusal clauses allow drug
distributors, such as pharmacists, to refuse to dispense birth con-
trol, even if a valid prescription is provided.217 While these clauses
were originally created to ensure that a healthcare provider “was
not forced” to perform an abortion,218 they are now being directed at
emergency and oral contraceptives.219 This is attributable to extrem-
ist groups that believe “that even basic oral and implant contracep-
tives act as abortifacients.” 220 By granting OTC access, the right to
restrict access to contraception through refusal will be removed.
A. The FDA Switch Process
The FDA regulates prescription drugs, OTC medications, and
is responsible for switches from one to the other.221 To change the
classification of a drug from prescription to OTC, the FDA protocol
must be followed, large fees must be paid, and heaps of evidence
about safety and efficacy must be provided.222 An FDA prescription
drug switch can be initiated by the following parties: (1) the FDA
Commissioner; (2) any person who files a citizen petition; or (3) the
drug manufacturer.223 The petitioning party must pay a roughly one-
million dollar filing fee to start the process and must submit exten-
sive research about the drug.224 Although the Commissioner or a
citizen is technically allowed to petition for a drug switch, pharma-
ceutical manufacturers are often the only party who can provide
detailed safety information and afford the steep fees.225 However,
pharmaceutical companies have no incentive to request a change
because they make more from prescription insurance payments
than they would if contraception was in the competitive market.226
215. Id.
216. LaSpina et al., supra note 211, at 404–05.
217. Id. at 391–92.
218. Id. at 389.
219. Id.
220. Id. at 390.
221. Drugs, FOOD & DRUG ADMIN., http://www.fda.gov/aboutFDA/transparency/Basics
/UCM192696.htm [https://perma.cc/QUB2-WJP5].
222. Tummino v. Torti, 603 F. Supp. 2d 519, 525 (E.D.N.Y. 2009); Grossman, supra
note 210.
223. Tummino, 603 F. Supp. 2d at 525; see 21 U.S.C.A. §§ 353(b)(3), 355(c)–(d) (2006).
224. Grossman, supra note 210.
225. Brown, supra note 9.
226. Id.
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“Unsurprisingly, none of the[se] sponsors who profit from keeping
contraceptives Rx-only want to challenge [the] status.” 227 The FDA
switch process creates a deadlock that gives drug companies the
power to dictate the status of contraception based on ulterior motives.
B. Plan B and Politics
The ineffective and corrupt practices involved in the OTC switch
of Plan B serve as a warning of the possible difficulties that regular
oral contraception may face.228 The political schemes that were
evidenced by the egregious and unfounded determinations for Plan
B demonstrate that women’s health and autonomy is not the driving
motivation behind OTC contraception access.229 Given the tumultu-
ous political climate, it is highly probable that political agendas will
make the OTC switch difficult.230 Debates over contraception cover-
age already bog down the process, “with both Democrats and Repub-
licans hoping to score some political points with their own proposals
rather than working together.” 231 The current dissonance between
Republicans and Democrats may only increase the tension. If drug
makers do petition and the FDA requirements are met, history has
shown that there is still no guarantee that a fair ruling will be
rendered.232 After assessing the plight of Plan B and considering the
unsteady state of politics, companies will be hesitant to cough up
the one million dollar filing fee knowing that they may face an
uphill battle.
C. Refusal Clauses Are Legal Loopholes for Discrimination
Refusal clauses allow religious organizations to place barriers
between women and much needed contraception. By approving OTC
access to the pill, the FDA can remove the leverage that these
clauses hold. Roe v. Wade233 set off a “political firestorm” that led to
the creation of “refusal clause” statutes.234 Insurers, healthcare
227. Id.
228. See Kandalaft & Vicry, supra note 58, at 56.
229. LaSpina et al., supra note 211, at 404–06. See generally Grossman, supra note
210; Mencimer, supra note 190.
230. See generally Charlotte Alter, Why Over-the-Counter Birth Control Is Stalled,
TIME (Dec. 23, 2015), http://time.com/4132835/why-over-the-counter-birth-control-is
-stalled [https://perma.cc/CL9F-D3SN].
231. Id.
232. There is much evidence that f inancial, religious, and political factors take
precedence over women’s health. LaSpina et al., supra note 211, at 404–06; Grossman,
supra note 210; Mencimer, supra note 190.
233. Roe v. Wade, 410 U.S. 113 (1973).
234. LaSpina et al., supra note 211, at 388.
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providers, employers, hospitals and many other institutions and in-
dividuals were allowed to refuse to have anything to do with medical
treatment that went against the “individual’s or institution’s moral,
ethical, or religious beliefs.” 235 While these statutes were originally
targeted at abortions, they are now broadly interpreted to encom-
pass contraception.236 “[E]arlier concern over access to contraception
has re-emerged, pitting professional autonomy and individual
religious freedom against a woman’s right to reproductive health
care and right to autonomy in family planning.” 237 “Although states
may not constitutionally deprive women of access to contraception,”
providers and pharmacists are using refusal clauses as a “legal
loophole” to refuse to perform procedures, prescribe medication, or
fill prescriptions.238 By allowing OTC access to oral birth control,
physicians and pharmacists that are utilizing these backdoor poli-
cies will largely be taken out of the equation. Thus, women will be
left with more freedom to make personal choices about family plan-
ning without undue restrictions.
VII. CONSTITUTIONAL ISSUES
Both denial of OTC access to oral contraception and the man-
dating of pelvic examinations in order to disperse oral contraception
raise constitutional issues regarding the Fifth Amendment’s Due
Process guarantee and the Fourteenth Amendment’s Equal Protec-
tion Clause.
A. Contraception and Case Law
The Supreme Court decisions in Griswold v. Connecticut,239
Eisenstadt v. Baird,240 and Carey v. Population Services Interna-
tional241 support that access to contraception is a fundamental right.
In Griswold, restricting a married couple’s access to contraceptives
was deemed a violation of the right to privacy.242 The right to use con-
traception was expanded to unmarried people in Eisenstadt.243 The
235. Id.
236. Id. at 389 (elaborating on how refusal clauses were enacted to protect healthcare
providers from being forced into performing abortions but now are being used against
family planning devices).
237. Id.
238. Id. at 390.
239. Griswold v. Connecticut, 381 U.S. 479 (1965).
240. Eisenstadt v. Baird, 405 U.S. 438 (1972).
241. Carey v. Population Servs. Int’l, 431 U.S. 678 (1977).
242. Griswold, 381 U.S. at 485.
243. Eisenstadt, 405 U.S. at 453.
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Court stated that “[i]f the right [to] privacy means anything, it is the
right of the individual, married or single, to be free [of] unwarranted
governmental intrusion into matters so fundamentally affecting a per-
son as the decision whether to bear or beget a child.”244 Thus, the fun-
damental right was extended to a “right to procreative privacy.” 245
The right was implicitly extended to distribution of contraception in
Carey.246 The Court found “that a law [restricting] the display, ad-
vertisement, and distribution of [birth control] was unconstitutional
and [specified] that government restrictions on contraceptive access
must meet strict scrutiny.” 247 The Court reasoned that access to
contraception is an integral part of the constitutional right to make
childbearing decisions and that it should be free from “unjustified
intrusion by the [s]tate.” 248
It is established that women have a strong right to a “dignity
interest in bodily integrity.” 249 Roe v. Wade250 and Planned Parent-
hood v. Casey251 are landmark decisions that weighed a woman’s right
to bodily integrity against the government’s interests in guarding
life and health.252 Roe made it clear that the right to privacy pro-
tected a woman’s decision of whether to terminate a pregnancy.253
This leads to an inference that deciding to prevent pregnancy “is
also a fundamental right [included] in the right to privacy.” 254 Casey
established that dignity and autonomy are protected by the Consti-
tution and that “[a]t the heart of liberty is the right to define one’s
own concept of existence, of meaning, of the universe, and of the
mystery of human life.” 255 While these cases addressed abortion rights
specifically, more recently Tummino v. Hamburg built upon these
foundations and granted OTC access to Plan B without age restric-
tions.256 Many argue that Tummino was also only applicable in an
244. Id.
245. Scout Richters, The Moral Interception of Oral Contraception: Potential Constitu-
tional Claims Against the FDA’s Prescription Requirement for a Progestin-Only Birth
Control Pill, 22 J.L. & POL’Y 393, 417 (2013). See also Carey, 431 U.S. at 687 (stating “the
Constitution protects individual decisions in matters of childbearing from unjustif ied
intrusion by the State. Restrictions on the distribution of contraceptives clearly burden
the freedom to make such decisions.”).
246. Carey, 431 U.S. at 700–02.
247. Richters, supra note 245, at 417.
248. Carey, 431 U.S. at 687.
249. Dixon, supra note 11, at 183.
250. Roe v. Wade, 410 U.S. 113 (1973).
251. Planned Parenthood of Se. Pa. v. Casey, 505 U.S. 833 (1992).
252. Dixon, supra note 11, at 184.
253. Richters, supra note 245, at 418.
254. Id.
255. Planned Parenthood, 505 U.S. at 851.
256. See generally Tummino v. Hamburg, 936 F. Supp. 2d 162 (E.D.N.Y. 2013).
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abortion context, but it has never been established that Plan B has
any effect after an egg has been fertilized.257 Further, the U.S. Govern-
ment Accountability Office actually stated that these contraceptives
“have not been shown to cause a postfertilization event—a change
in the uterus that could interfere with implantation of a fertilized
egg.” 258 Thus, it can be inferred that the constitutionally protected
right extends past abortion to non-emergent oral contraception.
B. Fifth Amendment Substantive Due Process Violations
If an FDA application for OTC oral birth control was denied, the
reasoning would most likely be that the “prescription requirement
serves the government’s compelling interest in protecting women’s
health,” 259 but this claim cannot be substantiated. To disprove a
Due Process claim, the FDA would be required to show that the
prescription requirement was narrowly tailored to serve this govern-
mental interest.260 The government would not be able to show that
women’s health is the reason for the denial because overwhelming
evidence proves otherwise.261
Determining whether or not the FDA should make a drug avail-
able OTC hinges on its safety and efficacy,262 and there are numerous
reasons why OC fulfills the requirements. First, there are very few
women that have contraindications for oral contraception use, but
the prescription requirement is overly inclusive because it is applied
to all women.263 The FDA routinely allows dangerous, even lethal,
drugs to be distributed with the caveat that they have a label speci-
fying the contraindications.264 Oral contraceptives are among some
of safest drugs that could be sold OTC,265 and labeling is adequate
to alert the small number of women that may experience issues.266
Additionally, studies have shown that women can effectively self-
screen for contraindications267 and can make an accurate assessment
257. Id. at 165 (citing the U.S. Government Accountability Office (GAO)).
258. Id. (quoting the GAO).
259. Richters, supra note 245, at 419.
260. See id. at 416.
261. Id. at 421.
262. Theresa M. Michele, Regulatory Approaches for Prescription to OTC Switch, FOOD
& DRUG ADMIN. (July 2, 2015), http://www.fda.gov/downloads/drugs/newsevents/ucm4548
15.pdf [https://perma.cc/5CL9-QQLF].
263. Richters, supra note 245, at 419.
264. Id. at 419–20.
265. Cf. Tummino v. Torti, 603 F. Supp. 2d 519, 523 (E.D.N.Y. 2009).
266. Richters, supra note 245, at 424.
267. Daniel Grossman et al., Accuracy of Self-Screening for Contraindications to
Combined Oral Contraceptive Use, 112 OBSTETRICS & GYNECOLOGY 572, 572 (2008).
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of their risk after reading a label. Most healthcare providers deter-
mine whether to prescribe birth control “almost entirely by hearing
a recitation of the woman’s medical history.” 268 Consultation with
a pharmacist or with alternate methods, such as information kiosks,
can provide the same level of guidance and consideration given by
a healthcare provider.269 Most importantly, a visit to a healthcare
provider has actually been shown to result in “[higher] health risks
and poorer health outcomes” due to additional procedures that are
unnecessarily performed.270 Lastly, prescription requirements deter
and restrict many women from getting access to birth control, lead-
ing to an increase in unintended pregnancies.271 “Aborti[ons] . . . or
carrying a pregnancy to full term both [result in] higher risks” than
those associated with oral contraception.272 Therefore, there is a
much greater risk to women’s health by retaining the prescription
requirement.
The pelvic examination requirement is also unconstitutional be-
cause the government cannot establish that the requirement is nar-
rowly tailored to protecting women’s health from the adverse effects
of oral contraception. “[T]he pelvic exami[nation] does not serve its
stated purpose, it is not necessary, and it is overly broad.” 273 The
purpose of the exam is to identify women who are susceptible to the
side effects of oral contraception and to restrict them from receiving a
prescription.274 The exam does not accomplish this goal because oral
contraception is not definitively linked to cervical cancer, the exam is
inadequate at detecting problems, alternative methods are just as
reliable and less invasive, “and the requirement [can] actually in-
crease[ ] risks” to women.275 “Under strict scrutiny review, a legisla-
tive rationale based on a mere associat[ed] correlation is insufficient
justification for restricting a constitutional right.” 276
Because it is claimed that the pelvic exam screens for cancer,
the government has to show that oral birth control causes cervical
cancer.277 Initially, family planning clinics required annual pelvic
exams because they had a hunch that oral contraception may cause
cervical cancer, but a causal connection between the two has never
268. Richters, supra note 245, at 420.
269. Id. at 420–21.
270. Id. at 421.
271. Id. at 398.
272. Id. at 421.
273. Dixon, supra note 11, at 184.
274. Id.
275. Id. at 185.
276. Id.
277. Id.
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been found.278 Ironically, not only is oral contraception not linked to
cervical cancer, but it “may actually protect against these [types of ]
cancers.” 279 Women on the birth control pill are approximately half
as likely to develop “ovarian and endometrial cancer as do nonus-
ers.” 280 Furthermore, pelvic examinations do not effectively screen
for ovarian cancer because they do not indicate women who have
precancerous lesions or human papillomavirus (HPV).281 Fifteen to
thirty percent of women with lesions will receive a negative result
from a pap smear, despite the test being correctly administered and
interpreted.282 While pelvic examinations can detect HPV, “[out] of
the millions of [cases], only a few [women] will . . . develop cervical
cancer.” 283 These tests are too broad and cannot accurately predict
who will actually develop cervical cancer.284 In addition to the test-
ing inconsistencies, over-screening causes harm because it leads to
false positives, which in turn requires additional testing or surgery
that causes discomfort, added costs, and risks.285 Women who are
denied oral contraception because of contraindications, inability to
afford the office visit, or because of refusal to submit to this exam
are left with less reliable birth control methods, resulting in an
increase in pregnancies.286 Full-term pregnancy and abortions have
substantially greater risks than utilization of oral contraception.287
Therefore, oral contraception poses lower risks, is more effective
than other birth control methods, and can help women avoid risks
associated with unplanned pregnancies and abortions.288 The nega-
tive effects of requiring a pelvic exam greatly outweigh any benefit
that it may provide.289
Pelvic examinations are not needed to prescribe hormonal con-
traception because the results do not have any bearing on whether
a patient receives a prescription.290 Most physicians prescribe based
only on verbal information provided by the patient.291 European phy-
sicians have found that pelvic exams are “irrelevant and unnecessary
278. Cf. id. at 85 n.49.
279. See Dixon, supra note 11, at 185–86.
280. Id. at 188.
281. Id. at 186.
282. Id.
283. Id.
284. See id.
285. See Westhoff et al., supra note 150, at 7.
286. See Dixon, supra note 11, at 187.
287. Id.
288. See id. at 185–87.
289. See id. at 188–89.
290. Id. at 189.
291. See Richters, supra note 245, at 420.
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barriers to contraception accessibility.” 292 The FDA, Planned Par-
enthood, and other family planning organizations allow women to
delay the pelvic exam for up to three months after administering
hormonal contraception.293 This demonstrates that the exam is not
necessary to safely administer oral contraception. ACOG stated that
“cervical cancer screening or sexually transmitted infection (STI)
screening is not required for initiating OC use and should not be
used as barriers to access.” 294 Alternate testing that is less invasive
has been found to produce better detection results of cervical cancer,
HPV, and Chlamydia than a pelvic exam.295 Thus, pelvic exams are
not needed to determine whether or not oral contraception can be
safely administered.
Because pelvic examinations can increase risks to women’s
health and the requirement of this testing is unnecessary, pelvic
examinations are not narrowly tailored to protect women’s health
from the side effects of oral contraception. Women have a constitu-
tionally protected right to dignity and bodily integrity, and the weak
reasoning provided by the government does not justify violating
these rights. This is a violation of the Due Process Clause, and
women should not be forced to adhere to unconstitutional barriers
that prevent access to oral contraception.
C. Fourteenth Amendment Equal Protection Violations
The prescription requirement for oral contraception violates the
Equal Protection Clause because it has both a disparate impact on
women and a discriminatory purpose behind the requirement.296 “The
disparate impact of the prescription requirement is evident: only
women use oral contraception and therefore are the only sex sub-
jected to the prescription requirement.” 297 According to Village of
Arlington Heights v. Metropolitan Housing Development Corp., courts
must look at circumstantial and direct evidence of intent inclusive
of the historical background, the legislative history and “[d]epartures
from the normal procedural sequence.” 298 The obvious suppression
292. See Dixon, supra note 11, at 189.
293. Id. at 189–90 n.79.
294. OVER-THE-COUNTER ACCESS, supra note 15, at 3.
295. See Dixon, supra note 11, at 190–91 (concluding that DNA tests not conducted
in conjunction with pelvic exams, are better at detecting cervical abnormalities that
indicate a risk of cervical cancer development). Self-collected vaginal swabs accurately
detect abnormalities and can serve as a substitute for pap screening. Id. at 191.
296. See Richters, supra note 245, at 423.
297. See id.
298. Village of Arlington Heights v. Metro. Hous. Dev. Corp., 429 U.S. 252, 266–68
(1977).
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of the pill and women’s rights, including the criminalization of con-
traception distribution, provides glaring evidence of discrimina-
tion.299 Starting in 1873, Congress passed the Comstock Law, which
labeled birth control as an obscenity and outlawed its distribution.300
Then in the early 1900s, women were encouraged by society and re-
ligious organizations to engage in highly risky birth control proce-
dures such as the Rhythm Method.301 It was not until the 1960s that
the pill was offered as a contraceptive method, but the Vatican
would not support the drug and some states still had laws making
birth control use a crime.302 It was not until Eisenstadt v. Baird in
1972, that the Supreme Court stopped states from standing in the
way of birth control distribution to single individuals.303 While birth
control has evolved over the last fifty years, Tummino v. Hamburg
demonstrates that discrimination and biased government involve-
ment is not a thing of the past.304 The government openly recognizes
that the FDA alone is the only party with the “necessary information
and scientific expertise to assess the data and information required
to make a determination that a drug is safe and effective.” 305 In
Tummino, the court highlighted the egregious deviation from this
principal and stated:
This salutary principle was flagrantly violated by Secretary
Sebelius, who completely lacks the “necessary information and
scientific expertise to assess the data and information required
to make a determination that a drug is safe and effective,” and
299. See, e.g., A Brief History of Birth Control: From early contraception to the birth
of the Pill, TIME (May 3, 2010), https://content.time.com/time/magazine/article/0,9171
,1983970,00.html [https://perma.cc/LAQ8-GEUY].
300. Megan Gibson, The Long, Strange History of Birth Control, TIME (Feb. 2, 2015),
http://time.com/3692001/birth-control-history-djerassi [https://perma.cc/2PCP-R94P].
301. Rhythm Method, supra note 42. The Rhythm Method is a method of birth control
that required women to abstain from sex halfway through their menstrual cycle when
she was most fertile. Id.
302. Frances Kissling, How the Vatican Almost Embraced Birth Control, MOTHER
JONES (May/June 2010), http://www.motherjones.com/politics/2010/04/catholic-church
-vatican-bishops-birthcontrol [https://perma.cc/LWC6-D3EU]; 100 Years of Birth Control:
How access to contraception revolutionized women’s lives, from 1914 to today, PLANNED
PARENTHOOD, https://plannedparenthoodaction.org/uploads/f iler_public/ed/78/ed78a43a
-e466-4194-870c-251794d9d22b/7-16-14-birth-control-timeline-final.pdf [https://perma
.cc/D452-DT7Y]. In 1961, it was a crime to use birth control in Connecticut despite the
FDA approving a pill for contraceptive use. See Time line of birth control, YEAPEOPLE
.COM, http://www.yeapeople.com/BirthCtrl.html [https://perma.cc/R6PP-LABD].
303. See Eisenstadt v. Baird, 405 U.S. 438, 447 (1972) (concluding that a state statute
barring unmarried people from obtaining contraception violated the Equal Protection
Clause because there was no rational basis for treating similarly situated married and
unmarried people differently).
304. See generally Tummino v. Hamburg, 936 F. Supp. 2d 162 (E.D.N.Y. 2013).
305. Tummino v. Hamburg, 936 F. Supp. 2d 198, 201 (E.D.N.Y. 2013) (internal cita-
tions omitted).
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whose role in the process has been circumscribed by Congress as
well as by the delegation to the Commissioner of any authority
that the Secretary may have—a clear recognition by Congress
and the Secretary of her lack of competence in this area. Yet, in
something out of an alternate reality, the defendants seek a stay
to pursue an appeal that would vindicate the Secretary’s disre-
gard of the very principle they advocate.306
The continued, meritless reasoning behind the government’s
actions have no explanation other than flagrant discrimination,
perpetuating unequal medical standards for women.
Pelvic examination mandates are unsubstantiated healthcare
burdens that unequally effect women and minorities.307 The Equal
Protection Clause “[requires] that a state must treat similarly situ-
ated” people in the same manner.308 Publicly funded family planning
services require pelvic exams for the purposes of “detecting sexually
transmitted diseases, pelvic inflammatory disease, or cancer.” 309
There is a lack of evidence showing any connection between oral con-
traceptive use and the factors detected by the exam, showing that
there is an “illegitimate purpose behind the requirement.” 310 While
women are required to undergo this invasive procedure to acquire
birth control, men can readily get condoms and prescription en-
hancement drugs without undergoing STD or prostate screenings,
despite both situations presenting the same opportunity to impose
preventative testing.311 Additionally, racial groups are also dispa-
rately impacted by the prescription birth control requirements.312
Income status and race are closely linked in the United States, and
racial and ethnic minorities utilize publicly funded health clinics at
a disproportionally high rate.313 Title X clinics (publicly funded
clinics) mandate a pelvic examination for contraceptive access, and
any woman who declines to consent to this testing is denied a pre-
scription.314 “Relegating women who refuse pelvic exams and cannot
afford private physicians to contraceptive methods with significantly
lower efficacy rates will result in many more unintended pregnancies
for minority women than for nonminority women.” 315 This result
306. Id. (internal citations omitted).
307. See Dixon, supra note 11, at 198.
308. Id. at 196.
309. Id. (internal citations omitted).
310. Id. at 202.
311. Id. at 196–97.
312. See id. at 200 n.153.
313. See Dixon, supra note 11, at 200.
314. Id. at 201.
315. Id.
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creates an even larger disparate impact on minorities who are already
at high risk.316 Women and minorities are placed in a compromising
and unjust position. The obvious disparate impact coupled with on-
going discrimination substantiates an Equal Protection violation.
VIII. POSSIBLE SOLUTIONS
A. Pharmacy Distribution
States have begun to take responsive measures to the prescrip-
tion drug deadlock, but they may prove to be an inefficient overall
solution. Both Oregon and California passed legislation allowing
contraception to be dispensed with the approval of a pharmacist.317
After answering a short twenty-question self-assessment and paying
roughly twenty-five dollars, women can walk away with birth con-
trol.318 Seemingly, this is a straightforward and effective remedy to
improve contraception access, but there are still barriers and dis-
crepancies that could render these programs partially ineffective.
In Carey v. Population Services International, the Supreme
Court declared that a law making it criminal to advertise, display,
or distribute contraception to a person under sixteen, or for anyone
other than a pharmacist to distribute contraceptives to people over
fifteen was unconstitutional.319 The Court found that restricting
distribution of birth control to pharmacists “unduly restricted access
to birth control (unjustifiably infringing the right to control procre-
ation) and that the law violated the rights of those under sixteen to
have access to contraceptives.” 320 A case could be made that allow-
ing pharmacists to be the gatekeepers for birth control distribution
could create a similar situation.
Another issue is availability. Eighteen months after California’s
governor signed the law allowing pharmacists to dispense birth control
without a physician prescription, only a handful of pharmacies were
participating.321 The new regulations require state-mandated train-
ing prior to distribution, and many of the big box pharmacies, such
as Walgreens and Rite Aid, are simply hesitant to undergo training
316. Id.
317. See Belluck, supra note 32.
318. Id.
319. Dixon, supra note 11, at 183.
320. Id.
321. Kelly O’Mara, Law Allows Women to Obtain Birth Control Without Prescription,
But Few Pharmacies Offer Service, KQED NEWS (May 19, 2016), https://ww2.kqed.org
/stateofhealth/2016/05/19/law-allows-women-to-obtain-birth-control-without-prescription
-but-few-pharmacies-offer-service [https://perma.cc/6FP3-LU9Q].
2
SEX, DRUGS, TRUMP AND BIRTH CONTROL 331
and implement formalities without knowing the financial impact.322
In May of 2016, it is estimated that only 100 out of 7,000 pharma-
cies were participating.323 Hurdles such as having to provide extra
staff to answer incoming doctor calls while another pharmacist
conducts a consultation—or having to provide a private consultation
room—increase resistance.324 At the end of the day, the regulations
are not mandatory and pharmacies are leery of taking part without
a financial incentive.325 Further, even if the pharmacy does take
part, refusal clauses still allow employees to refuse to dispense birth
control if they feel that it conflicts with their personal beliefs.326
Distribution aside, there are continuity issues that could impact
both pharmacies and consumers. In Oregon, “[o]nly self-adminis-
tered oral or transdermal products” are dispensed327 while Califor-
nia offers self-administered hormonal birth control, including “pills,
patches, injections and vaginal rings.” 328 Authorizing different
products per state creates consumer and pharmacist confusion. Big
pharmacies that seek to implement programs across all of their
locations will not be able to create a standardized system because
of the differing legislation.329 This difficulty could lead to further
resistance. From a consumer perspective, women who are regularly
taking one type of birth control may be forced to change their treat-
ment regimen because of availability.
The continuity issue is further problematic when examining the
nation as a whole. Highly conservative states may refuse to adopt
similar legislation. When originally passed, the Affordable Care Act’s
requirement that all health plans pay for prescription birth control
was highly controversial and was “met with emotional[,] political[,]
and religious opposition.” 330 Undoubtedly, the same backlash will
befall this type of legislation in conservative states and could block
the passage of the regulations. While these state initiatives are a step
in the right direction, the potential loopholes, lack of consistency,
322. See, e.g., id.
323. Id.
324. Id.
325. Id.
326. Pharmacist Conscience Clauses: Laws and Information, NAT’L CONFERENCE OF
STATE LEGISLATURES ( last updated May 2012), http://www.ncsl.org/research/health
/pharmacist-conscience-clauses-laws-and-information.aspx [https://perma.cc/BM3T-N9L4].
327. Frequently Asked Questions, OR. STATE PHARMACY ASSOC., http://www.oregon
pharmacy.org/hb2879---hormonal-birth-control-faqs [https://perma.cc/C65C-P2T9].
328. Karlamangla, supra note 35.
329. O’Mara, supra note 321.
330. Pam Belluck, Birth Control via App Finds Footing Under Political Radar, N.Y.
TIMES (June 19, 2016), https://www.nytimes.com/2016/06/20/health/birth-control-options
-websites.html [https://perma.cc/QY3X-TZ6H].
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and strong opposition may greatly impinge on the applicability of
these programs.
B. Online Options
New grassroots efforts to combat availability issues have given
way to a new supply method: online birth control providers.331 Com-
panies such as Nurx, Maven, Lemonaid and Planned Parenthood
Care allow patients to get a prescription and order pills through a
website without a physical visit to a physician.332 Some of the online
services even offer video conferencing and messaging with nurse
practitioners.333 “Providers recommend a medication on the spot and
order it to be sent to a pharmacy near the patient.” 334 Women who
have difficulty getting off work for an office visit or who cannot
afford extenuating medical costs can easily procure the medication
that they need. Luckily, these applications have managed to fly
under the radar and have encountered little opposition thus far.335
By circumventing doctor’s visits and unnecessary testing, the pa-
tient will incur less cost, see faster service, and achieve easier access
to much needed contraception.336 Insurance can be used for the ser-
vice, and affordable options are available for those without coverage,
as well.337 These companies sound like the perfect answer for acces-
sibility, but there are a few snags.
First, the biggest issue is that this method suffers from the
same distribution issues as the pharmacy option. These sites can
only service an extremely limited amount of states and may not be
able to expand to cover the entire nation.338 Second, shipping delays
could potentially cause issues with the timing of OC. If the prescrip-
tion arrives late or a person waits until the last minute to order,
they may fall behind on their schedule, leaving them unprotected for
a small period of time. Lastly, indigent women without access to a
computer or the Internet would not be able to take advantage of
these services. This would effectively create a discriminatory effect
and ignore one of the largest groups that experiences unintended
331. Id.
332. Stephanie M. Lee, Now You Can Get Birth Control Through These Apps, BUZZ-
FEED (Jan. 11, 2016, 6:38 PM), https://www.buzzfeed.com/stephaniemlee/these-apps-de
liver-birth-control-to-your-door?utm_term=.td7637NNJ#.qx1PbXRRO [https:/ perma.cc
/8HKL-2U75].
333. Id.
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335. Id.
336. Id.
337. Id.
338. Belluck, supra note 330.
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pregnancies. While this is a positive option, there must be larger
expansion to make this a viable option for women in every state.
C. Can Acts Produce Action?
In an effort to combat the fatal flaw of the FDA switch process,
the Allowing Greater Access to Safe and Effective Contraception Act
was introduced.339 This bill proposed to incentivize drug companies
if they sought FDA approval of OTC contraception.340 Unfortunately,
this Act was met with disapproval because it did not address insur-
ance coverage for OTC contraception and without a solution, many
feared that costs would skyrocket.341 A second Act, the Affordability
Is Access Act, was later proposed to provide answers for the defi-
ciencies in the previous initiative:342
The purpose of this Act is to ensure timely access to affordable
birth control by requiring coverage without cost-sharing for oral
birth control for routine, daily use that is approved by, or other-
wise legally marketed under regulation by, the Food and Drug
Administration for use by women without a prescription.343
The Act specifically references that more than 55,000,000 women
benefitted from cost-free benefits that amounted to a savings of
more than $483,000,000 in “out-of-pocket costs.” 344 While this Act pro-
posed an appropriate solution for access and cost, the bill was not
passed.345 The success of future attempts to enact this Act may have
an even lower success rate if the ACA is repealed and the birth control
mandate ends. Politicians may support OTC access but will be reluc-
tant to vote for an act that reinstates the birth control mandate.
CONCLUSION
After over a decade, birth control is still being shackled by out-
dated perceptions, corruption, and unnecessary government control.
339. Kimberly Leonard, On Capitol Hill, a Push to Make the Pill Over the Counter, U.S.
NEWS (June 9, 2015, 7:11 PM), https://www.usnews.com/news/articles/2015/06/09/on-capi
tol-hill-a-push-to-get-the-birth-control-pill-over-the-counter [https://perma.cc/4NE2-9AS2].
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343. Affordability Is Access Act, S.1532, 114th Cong. § 2 (2015), http://www.help.sen
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344. Id. § 3(7).
345. S. 1532 (114th): Affordability Is Access Act, GOVTRACK (Dec. 8, 2016), https://
www.govtrack.us/congress/bills/114/s1532 [https://perma.cc/Z9ZH-R4ZK].
<<
WILLIAM  & MARY JOURNAL OF WOMEN AND THE LAW           [  V    o l. 24:295
The new administration’s proposed repeal of the ACA creates an
expedient need to find a permanent solution offering accessible and
affordable birth control. Unplanned pregnancies are on the rise due
to prohibitive costs and poor access, but technological advances and
legislation could potentially remedy these problems. Having an
unplanned pregnancy rate of fifty percent indicates that prescription-
only OC distribution is inadequate and that there are too many
barriers blocking women from acquiring contraception. Offering
OTC access will remedy this situation and lower the unplanned
pregnancy rates.346 In turn, the government will save billions of
dollars that can be utilized to lower or fully cover the cost of OC.347
The requirement of yearly pelvic examinations as a prerequisite
for an OC prescription is outdated and ineffective. Unrelated testing
only serves to alienate women by raising costs, causing undue em-
barrassment, disproportionately affecting minorities, and by disre-
garding a woman’s autonomy.348 Innovative testing for sexually
transmitted diseases, HPV, and cancer offer effective alternatives
to these exams and should be utilized. Additionally, gynecological
experts and authorities, such as the ACOG, recognize the lack of
connection between making OC dependent on unnecessary gynecol-
ogical services and recommend breaking down these unnecessary
barriers.349 The lack of correlation between pelvic examinations and
oral birth control, coupled with the availability of effective, substitute
testing, demonstrates that these archaic practices should not continue.
Physicians continue to support prescription birth control re-
quirements because of financial incentives.350 The result is that they
conduct unnecessary testing, pelvic examinations, and procedures,
often disregarding an individual patient’s needs.351 Pharmaceutical
companies are similarly situated because they also gain financially
by keeping oral birth control prescription only.352 It is unrealistic to
expect biased physicians and drug makers to objectively make de-
terminations regarding OC. The obvious solution is to offer OTC OC
to take the power out of the hands of the physicians and place it in
those of the patients. This in turn will remove the opportunity to ex-
ploit patient care and will lower the incidence of false medical
claims.353
346. ACCESS TO CONTRACEPTION, supra note 8, at 2.
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There are too many outside influences that restrict access to
birth control. First, the FDA switch process is a broken mechanism
that invites corrupt parties and politicians to justify unsubstanti-
ated blocking of OTC access. The FDA switch process cannot be
directed by pharmaceutical companies that profit more from keep-
ing drugs out of the competitive market. This is counterintuitive
because it stops women from gaining easier access to much needed
drugs and does not allow the open market to drive down costs.
Second, politicians cannot constantly dictate the fate of birth con-
trol. Their continuous meddling only serves to deter possible compa-
nies from petitioning for an OTC drug switch. Additionally, constant
strife between Democrats and Republicans makes coming to an
amicable solution almost impossible. Lastly, refusal clauses provide
legal loopholes for religious organizations. Religious beliefs should
not dictate whether a woman has access to birth control, and these
clauses must be circumvented to ensure that this does not happen.
The barriers to obtaining contraception are infringements on
women’s rights and are about more than autonomy; they are out-
right constitutional violations. Sadly, a cause of action challenging
constitutionality cannot be brought until the FDA denies a switch
application, and a switch application will not be filed because drug
makers have no desire to make birth control OTC. This is a pur-
posely constructed self-defeating process. Women are being strong-
armed into complying with unconstitutional practices without being
offered proper protection. Thus, other alternatives must be utilized
to bypass the FDA and stop these egregious violations.
A solution will not be effective enough unless it can perma-
nently secure OTC access to oral contraception nationwide. State
initiatives that offer access through pharmacists and online retail-
ers are steps in a positive direction, but they do not offer protection
for all women and they have serious application issues. There are
too many loopholes and inconsistencies for this to be the most effective
solution. Providing permanent legislation that grants OTC contra-
ception access and mandates that the government will substantially
or fully pay for OC is the best solution. The Affordability Is Access
Act proposes these elements and addresses both cost and access, but
the bill died in a 2015 congressional session. In lieu of the ACA
repeal, a new Act that omits the coverage requirements has a better
chance of approval, but there must be a strong push from Donald
Trump and politicians to build the necessary momentum required.
Ultimately, online- and pharmacy-prescribed contraception provide
an adequate interim option while legislation is being developed, but
an Act will be the only means to provide a permanent solution.

